Genocea Provides First Quarter 2020 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Biosciences (GNCA) Misses Q1 EPS by 11c
April 30, 2020 7:11 AM EDTGenocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.46), $0.11 worse than the analyst estimate of ($0.35).
Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2021.
For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.
... More